Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 344

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 344
---
 been initiated; • the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value; • completion of the sale should be foreseeable within the 12 months following the date of reclassification to Assets held for sale ; and • actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Before initial reclassification of the non-current asset (or asset group) to Assets held for sale , the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards. Subsequent to reclassification to Assets held for sale , the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized. From the date of reclassification: • property, plant and equipment, right-of-use assets and intangible assets are no longer subject to individual depreciation, amortization or impairment; and • the share of profits and losses from investments accounted for using the equity method is no longer recognized. In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held for sale assets or liabilities within the balance sheet line items Assets held for sale or Liabilities related to assets held for sale , provided that the disposal satisfies the IFRS 5 classification criteria. The profit or loss generated by a held for sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group: • represents a separate major line of business or geographical area of operations; or • is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or • is a subsidiary acquired exclusively with a view to resale. In accordance with IFRS 10, intragroup balances and transactions relating to held for sale entities are eliminated. In the absence of any specific accounting treatment under IFRS 5, Sanofi has opted to eliminate transactions between discontinued operations and continuing operations so as to reflect the impact of such transactions consistently with the way they are presented in the income statement after effective loss of control. Events or circumstances beyond Sanofi’s control may extend the period to complete the sale or